Purpose: This study aims to evaluate the associations between genetic polymorphisms and the effect of sodium valproate (VPA) therapy in children with generalized seizures. Methods: A total of 174 children with generalized seizures on VPA therapy were enrolled. Steady-state trough plasma concentrations of VPA were analyzed. Seventy-six single nucleotide polymorphisms involved in the absorption, metabolism, transport, and target receptor of VPA were identified, and their associations with the therapeutic effect (seizure reduction) were evaluated using logistic regression adjusted by various influence factors. Results: rs7668282 (UGT2B7, T > C, OR = 2.67, 95% CI: 1.19 to 5.91, P = 0.017) was more prevalent in drugresistant patients than drug-responsive patients. rs2242480 (CYP3A4, C > T, OR = 0.27, 95% CI: 0.095 to 0.79, P = 0.017) and rs10188577 (SCN1A, T > C, OR = 0.40, 95% CI: 0.17 to 0.94, P = 0.035) were more prevalent in drug-responsive patients compared to drug-resistant patients. Conclusion: In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction. Larger studies are warranted to corroborate the results.
Introduction
Sodium valproate (VPA), a gold standard antiepileptic drug for treating pediatric patients with various types of seizures, has a greatly varied treatment effect between individuals [1] . A study in France indicated that 22.5% of patients with epilepsy have drugresistant epilepsy [2] . However, the mechanisms of drug resistance are not well understood. Two factors are thought to be involved in the therapeutic effect of VPA: steady-state target site concentration and target receptor function. Steady-state target site concentration of VPA is affected by its absorption, metabolism, and transport through the blood-brain barrier [3] .
VPA is a fatty acid, thought to be absorbed by fatty acid binding protein 2 (FABP2) in the small intestine, and its effective dose influenced by the polymorphisms of FABP2 (163 G > A) [3] .
Mitochondrial b-oxidation and glucuronidation are two major pathways in VPA metabolism in adults [4] . However, the activity of glucuronidases are much lower in children than in adults, therefore, the mitochondrial b-oxidation might be the major pathway in the metabolism of VPA in children [5] . Genetic polymorphisms involved in the mitochondrial b-oxidation and Abbreviations: VPA, sodium valproate; FABP2, fatty acid binding protein 2; ABCB1, ATP binding cassette subfamily B member 1; ABCC2, ATP binding cassette subfamily C member 2; GABA, gamma-aminobutyric acid; ABAT, 4-aminobutyrate aminotransferase; GABR, GABA receptor; SCN, sodium voltage-gated channel; NMDA, N-methyl-D-aspartate; GRIN, glutamate ionotropic receptor NMDA type; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; 95% CI, 95% confidence interval; SNP, single nucleotide polymorphism; UGT2B7, uridine diphosphate glucuronosyltransferase family 2 member B7; CYP3A4, Cytochrome P450 family 3 subfamily A member 4; SCN1A, sodium voltage-gated channel alpha subunit 1; CYP2C9, cytochrome P450 family 2 subfamily C member 9.
glucuronidation of VPA were associated with its plasma concentration [6] [7] [8] [9] .
VPA needs to be transported into its target site to exhibit its physiological activity via various transporters such as ATP binding cassette subfamily B member 1 (ABCB1) and ATP binding cassette subfamily C member 2 (ABCC2). Some studies indicated that genetic polymorphisms of these transporters were associated with drug resistance in adult patients with epilepsy [10] [11] [12] [13] , however, other studies failed to find this association [14] [15] [16] .
VPA could inhibit gamma-aminobutyric acid (GABA) transaminase, which is encoded by 4-aminobutyrate aminotransferase (ABAT) gene [4] , and result in an increased concentration of GABA levels in the brain. Furthermore, VPA could enhance GABA receptor (GABR)-mediated inhibition via positive regulation of the receptors [17] , therefore genetic variants in GABR may influence the therapeutic response of VPA [16, [18] [19] [20] [21] . The high-frequency firing of neurons was reduced by blocking voltage-gated calcium channels, which are encoded by the sodium voltage-gated channel (SCN) gene family. Thus, SCN gene polymorphisms may be involved in the anticonvulsant activity of VPA [22] . Moreover, VPA could affect the neuronal excitation, which is mediated by the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors, encoded by glutamate ionotropic receptor NMDA type (GRIN) gene [23] . In addition, many concomitant antiepileptic drugs could influence VPA metabolism and effect [24] .
In the present study, children with generalized seizures on VPA therapy were enrolled. Genetic polymorphisms in genes involved in the absorption, metabolism, transport and target receptor of VPA were identified, and their associations with seizure reduction were analyzed.
Methods

Study design
This study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Signed informed consents were obtained from patients or their direct relatives. The inclusion criteria was as follows: (1) diagnosis meeting the criteria for generalized seizures [25] , (2) aged 2 to 18 years, (3) receiving VPA treatment, (4) without other serious disease. Exclusion criteria were severe renal, liver, or cardiac impairment, serious adverse drug reactions and loss to follow-up.
Patients were enrolled according to the above criteria. The demographic data, dosage regimens, seizure type [26] , concomitant antiepileptic drugs, and seizure frequency (prior to and 1-year after VPA treatment) were recorded. Reduced seizure frequency of more than 50% was regarded as drug-responsive epilepsy, less than or equal to 50% was defined as drug-resistant epilepsy [27] [28] [29] [30] . After regularly taking VPA for at least 30 days, blood samples were collected within 2 h prior to the next dose. After centrifuging at 5000g for 10 min, VPA concentration was obtained from the plasma, and the white blood cells were stored at À80 C for genotyping. A one-year follow-up was performed to evaluate the seizure reduction of VPA therapy. The association between genetic polymorphisms and seizure reduction was analyzed by PLINK software using logistic regression adjusted for gender, age, body weight, dosage form, dosing frequency, total daily dose, VPA plasma concentration and concomitant antiepileptic drugs.
Plasma concentration of VPA
The plasma concentrations of VPA were analyzed on an AXSYM automatic immunity analyzer (TDx, ABBOTT, USA) by fluorescence polarization immunoassay.
Genotyping
DNA was isolated by QIAamp DNA purification kit (Qiagen, Hilden, Germany). Genotyping was performed by MassArray method (Sequenom, USA) in Bio Miao Biological Technology (Beijing) [31] . Five percent of the total samples were measured repeatedly to control for analytical quality and reproducibility.
Statistical analysis
Statistical analysis was performed by SPSS (version 17.0, SPSS Inc., Chicago, USA) and PLINK (version 1.07, Shaun Purcell, Boston, USA) softwares. Continuous variables were expressed as mean AE SD and statistically examined using the student's t-test or nonparametric test. The classified variables were expressed as numbers or percentages and statistically analyzed by chi-square test. The association between genetic polymorphisms and seizure reduction was evaluated with PLINK software using linear regression adjusted by various factors including gender, age, body weight, dosage form, dosing frequency, total daily dose, VPA plasma concentration and concomitant antiepileptic drugs. The Minor Allele Frequency (MAF), genotype, Hardy-Weinberg Equilibrium (HWE) (P-value, chi-square test), odds ratio (OR) and its 95% confidence interval (95% CI), coefficient z-statistic, and P value (asymptotic P value for z-statistic) were calculated [32] . A P-value less than 0.05 was regarded as statistical significance.
Results
Characteristics of enrolled patients
A total of 174 Chinese children with generalized seizures (17 inpatients and 157 outpatients) from the Beijing metropolitan area were enrolled during January 2014 to December 2016, and their basic information and clinical characteristics are summarized in Table 1 (detail in Appendix A in Supplementary data). Gender, age, body weight, dosage form, dosing frequency, total daily dose and VPA plasma concentration were comparable between the therapy responsive and resistant groups.
Genotyping and its association with therapeutic effect
The genotyping results and basic information of selected single nucleotide polymorphism (SNP) are listed in Appendix A in Supplementary data. All of the analyzed SNPs were consistent with the HWE (P > 0.05). Three SNPs were associated with the seizure reduction ( Table 2 , Appendix B in Supplementary data). rs7668282 [uridine diphosphate glucuronosyltransferase family 2 member B7 (UGT2B7), T > C, OR = 2.67, 95% CI: 1.19 to 5.91, P = 0.017] was more prevalent in drug-resistant (seizure reduction 50%) patients than drug-responsive (seizure reduction >50%) patients. rs2242480 [Cytochrome P450 family 3 subfamily A member 4 (CYP3A4), C > T, OR = 0.27, 95% CI: 0.095-0.79, P = 0.017] and rs10188577 [sodium voltage-gated channel alpha subunit 1 (SCN1A), T > C, OR = 0.40, 95% CI: 0.17-0.94, P = 0.035] were more prevalent in drugresponsive patients compared to drug-resistant patients. Comparable steady state VPA plasma concentration was observed in different patient groups (Fig. 1 ).
Discussion
About 30-50% of a VPA dose is transformed into VPAglucuronide conjugate via UGT enzymes in the liver and subsequently excreted from the urine [33] . rs7668282 (C > T, MAF = 0.111), a SNP in the promoter of UGT2B7, was more prevalent in drug-resistant patients than drug-responsive patients (OR = 2.67, 95% CI: 1.19-5.91, P = 0.017). To our knowledge, there are no reports regarding the association of rs7668282 with VPA treatment response in patients with epilepsy, perhaps due to its extremely low MAF [0.080 in Han Chinese and 0.008 in Caucasian (White), data obtained from NCBI dbSNP database]. rs2242480 (C > T, MAF = 0.185), an intron variant of the CYP3A4 gene, was more prevalent in drug-responsive patients than drug-resistant patients (OR = 0.27, 95% CI: 0.095-0.79, P = 0.017). The exact mechanism of this variant in VPA treatment has not been clarified. The activity of glucuronidase is much lower in children than in adults; therefore, the mitochondrial b-oxidation might be the major pathway in the metabolism of VPA in children. Cytochrome P450 family 2 subfamily C member 9 (CYP2C9)-status guided VPA therapy could be used for the optimization of VPA dosing in Caucasian (White) children [5] . The low frequency of CYP2C9*2 and CYP2C9*3 genotype in the Han Chinese population (0.0017 and 0.040, data from 1000genomics), the reduced enzyme activity in rs2242480 carriers [34, 35] , and the influence of CYP3A4 polymorphisms on the metabolism of concomitant antiepileptic drugs [36, 37] might be explanations for this association.
VPA needs to be taken into the brain via various transporters in order to exhibit its anticonvulsant effect. ABCB1 and ABCC2 are two important transporters involved in the treatment response of patients with epilepsy, but research findings are contradictory. Some studies indicated that polymorphisms of ABCB1 [11, 13] and ABCC2 [10, 12] were associated with therapeutic response in patients with epilepsy, others failed to find the association [15, 16, 38, 39] . In the present study, three SNPs in ABCB1 and one SNP in ABCC2 were identified, none of which were associated with the effects reported in previous studies [15, 16, 38, 39] .
It has been suggested that VPA provides its antiepileptic activity by blocking off the sodium channel such as SCN1A, SCN2A, and SCN3A. Mutations in SCN1A/2A/3A were associated with epilepsy onset [40] . In the present study, rs10188577 (T > C, MAF = 0.216), an intron variant of SCN1A gene, was more prevalent in drugresponsive patients than drug-resistant patients (OR = 0.40, 95% CI: 0.17 to 0.94, P = 0.035). In 519 Caucasian (White) patients (aged 1-86 years) with epilepsy, more heterozygous mutation carriers (rs10188577) were found in drug-resistant group than drugresponsive group (48.3% vs 35.4%, P = 0.049) [41] . The study authors indicated that rs10188577 was associated with two neighbouring sodium channel genes, SCN7A and SCN9A (P = 0.025), and attributed their findings to transcription factors or methylation sites being affected by the presence of this variant. Kwan et al. [42] reported that rs10188577 was not associated with treatment response in 471 Chinese patients with epilepsy (aged 15 years or above). Despite the unknown effect of this variant on the antiepileptic drug response, differences in ethnicity, patients' basic information, and disease status in different studies might contribute to the contradictory results.
GABA is a well-known neurotransmitter that could bind to GABR to adjust the transport of chloride ions into the neuron. VPA could inhibit ABAT, a key enzyme in the metabolism of GABA, to exert its pharmacological ability. Thus variants of ABAT and GABR may affect the efficacy of VPA [18] [19] [20] [21] . Some studies found a protective effect of rs2279020 (G > A) in the GABRA1 gene in patients with epilepsy [18, 28] , but this was not confirmed in other studies [16] . rs211037 (C > T, GABA type A receptor gamma 2 subunit) is an independent risk factor for febrile seizure, and in linkage disequilibrium with rs210987 can contribute to febrile seizures and symptomatic epilepsy in Chinese [19] [20] [21] . Other studies revealed that rs211037 was not correlated with epilepsy susceptibility or drug resistance [18, 43] . In the present study, two variants of ABAT (rs1731017, A > G and rs1641021, C > T) and sixteen variants of the GABR family were identified but their associations with treatment effect were not as observed in previous studies [16, 18, 43] .
In summary, three variants in UGT2B7, CYP3A4 and SCN1A genes were associated with treatment efficacy in children with generalized seizures on VPA therapy. Other variants in various genes related to the absorption, metabolism, transport and target receptors of VPA were not associated with seizure reduction. In children with epilepsy, if the genotype of rs7668282 or rs10188577 is CC/CT, or if the genotype of rs2242480 is CT/TT, a higher VPA dose might be helpful for seizure control.
Deficiencies of the study
Limitations of the study: (1) variants with low frequency (MAF <0.05) were not analyzed; (2) the sample size (174 patients) was relatively small; (3) the influence of non-antiepileptic concomitant medications on the treatment response was not considered.
Conclusions
In children with epilepsy on VPA therapy, seizure reduction was associated with three genetic polymorphisms of UGT2B7, CYP3A4 and SCN1A genes. Larger studies are warranted to validate these results.
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